As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Analyst Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report) and keeping the price target ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

Ricci has spent his entire technology career in the pharmaceutical industry, beginning at Bristol-Myers Squibb, then Johnson ...

BMS said it will launch Cobenfy within the next ... glycine transporter 1 inhibitor iclepertin in phase 3, Newron Pharma's sodium channel blocker evenamide, which had encouraging phase 2/3 data ...

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... grew ...